DE69521536D1 - Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten - Google Patents

Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten

Info

Publication number
DE69521536D1
DE69521536D1 DE69521536T DE69521536T DE69521536D1 DE 69521536 D1 DE69521536 D1 DE 69521536D1 DE 69521536 T DE69521536 T DE 69521536T DE 69521536 T DE69521536 T DE 69521536T DE 69521536 D1 DE69521536 D1 DE 69521536D1
Authority
DE
Germany
Prior art keywords
csf
binding protein
pharmaceutically acceptable
tnf binding
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69521536T
Other languages
English (en)
Other versions
DE69521536T2 (de
Inventor
Gottfried Alber
Peter Angehrn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE69521536D1 publication Critical patent/DE69521536D1/de
Application granted granted Critical
Publication of DE69521536T2 publication Critical patent/DE69521536T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
DE69521536T 1994-02-04 1995-01-19 Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten Expired - Lifetime DE69521536T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810059 1994-02-04

Publications (2)

Publication Number Publication Date
DE69521536D1 true DE69521536D1 (de) 2001-08-09
DE69521536T2 DE69521536T2 (de) 2002-04-18

Family

ID=8218199

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69521536T Expired - Lifetime DE69521536T2 (de) 1994-02-04 1995-01-19 Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten

Country Status (16)

Country Link
US (2) US5776895A (de)
EP (1) EP0668077B1 (de)
JP (1) JP2765807B2 (de)
CN (1) CN1097468C (de)
AT (1) ATE202709T1 (de)
AU (1) AU693833B2 (de)
BR (1) BR9500436A (de)
CA (1) CA2139385C (de)
DE (1) DE69521536T2 (de)
DK (1) DK0668077T3 (de)
ES (1) ES2160643T3 (de)
GR (1) GR3036774T3 (de)
NZ (1) NZ270422A (de)
PT (1) PT668077E (de)
RU (1) RU2139084C1 (de)
ZA (1) ZA95679B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6419919B2 (en) * 1997-11-07 2002-07-16 John D. Mountz Method for the augmentation of gene expression
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
ES2239846T5 (es) * 1998-07-30 2011-03-04 The Government Of The United States Of America, As Repres. By The Secretary Of Health And Human Services, Nat. Inst. Of Health Mejora de la curación de heridas mediante la timosina beta-4.
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20080108560A1 (en) * 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
WO2004075918A1 (en) 2003-02-28 2004-09-10 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CN107207601A (zh) 2015-01-20 2017-09-26 Igm生物科学股份有限公司 肿瘤坏死因子(tnf)超家族受体结合分子及其应用
AU2018348138A1 (en) * 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396158A1 (de) * 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Herstellung des die pluripotente Granulozyt-Kolonie stimulierenden Faktors
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
DK0567566T4 (da) * 1991-01-18 2007-10-22 Amgen Inc Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
PT639079E (pt) * 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
EP0642356B1 (de) * 1992-05-05 2003-04-16 Aeres Biomedical Limited Antikörper gegen p-selectin und ihre verwendung

Also Published As

Publication number Publication date
CN1097468C (zh) 2003-01-01
CA2139385C (en) 2001-12-25
ZA95679B (en) 1995-08-08
EP0668077B1 (de) 2001-07-04
AU1146295A (en) 1995-08-17
BR9500436A (pt) 1995-10-17
CA2139385A1 (en) 1995-08-05
JP2765807B2 (ja) 1998-06-18
JPH07258300A (ja) 1995-10-09
AU693833B2 (en) 1998-07-09
NZ270422A (en) 1996-06-25
RU2139084C1 (ru) 1999-10-10
CN1111158A (zh) 1995-11-08
DK0668077T3 (da) 2001-10-08
EP0668077A1 (de) 1995-08-23
RU95101385A (ru) 1996-12-27
ATE202709T1 (de) 2001-07-15
ES2160643T3 (es) 2001-11-16
US5776895A (en) 1998-07-07
GR3036774T3 (en) 2002-01-31
DE69521536T2 (de) 2002-04-18
PT668077E (pt) 2001-12-28
US5750503A (en) 1998-05-12

Similar Documents

Publication Publication Date Title
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
BG101118A (en) Therapeutical compounds
EP0734723A4 (de) Therapeutisches präparat zur behandlung von hyperparathyroidismus bei dialysepatienten
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
EP0347899A3 (en) Pharmaceutical compositions on egg shell basis and their preparation and use
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
HK124595A (en) Anthocyanidins for the treatment of ophthalmic diseases
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
IL91152A0 (en) Furylthiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
CA2097878A1 (en) Therapeutic agent for neutropenia
EP0491873A4 (en) Therapeutic compositions; methods for treatment of hiv infections
EP0384302A3 (de) Verwendung von Ubenimex zur Hestellung eines Medikaments zur Behandlung des myelodysplastischen Syndroms
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
ATE99933T1 (de) Mittel zur behandlung von nierenbeschwerden.
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition